| » |
The development for this drug is based on TBL’s unique auto-immune technology platform. |
| |
Multiple sclerosis is an incurable autoimmune disease that affects the CNS through interplay of genetic and environmental factors. |
| » |
Certain environmental factors trigger the antibody generation and these antibodies are directed against the CNS specific Myelin antigens causing a damaging effect on the myelin sheath of the neurons. |
| » |
The B cells that produce the auto antibodies can also initiate/enhance Cell mediated immunity (T cells) on CNS through antigen presentation, further aggravating the condition. |
| » |
Our technology development is based on the removal of these auto reactive B cells thereby subdue both forms of immune attack considerably on CNS in the affected persons. |
| » |
The development for this drug is based on TBL’s unique auto-immune technology platform. |
| » |
TBL’s scientists have identified the specific antigens involved in generating the auto-antibodies and developed unique method in negating those.
|
| » |
Our technology is based on highly selective removal of auto reactive B cells subduing the immune attack considerably on CNS in the affected persons. |
| » |
Work on this technology is progressing well and pre-clinical studies are planned to commence during Q1 of 2010-11. |
